About: Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment
Creator	Azam, Salma Chang Hsin-I, Italy Criscuolo, Domenico Harrison, Emily Pecot, Chad Wu, Sherry
Source	Medline; PMC
abstract	Nucleic acid delivery for cancer holds extraordinary promise. Increasing expression of tumor suppressor genes or inhibition of oncogenes in cancer cells has important therapeutic potential. However, several barriers impair progress in cancer gene delivery. These include effective delivery to cancer cells and relevant intracellular compartments. Although viral gene delivery can be effective, it has the disadvantages of being immuno-stimulatory, potentially mutagenic and lacking temporal control. Various nanoparticle (NP) platforms have been developed to overcome nucleic acid delivery hurdles, but several challenges still exist. One such challenge has been the accumulation of NPs in non-cancer cells within the tumor microenvironment (TME) as well as the circulation. While uptake by these cancer-associated cells is considered to be an off-target effect in some contexts, several strategies have now emerged to utilize NP-mediated gene delivery to intentionally alter the TME. For example, the similarity of NPs in shape and size to pathogens promotes uptake by antigen presenting cells, which can be used to increase immune stimulation and promote tumor killing by T-lymphocytes. In the era of immunotherapy, boosting the ability of the immune system to eliminate cancer cells has proven to be an exciting new area in cancer nanotechnology. Given the importance of cancer-associated cells in tumor growth and metastasis, targeting these cells in the TME opens up new therapeutic applications for NPs. This review will cover evidence for non-cancer cell accumulation of NPs in animal models and patients, summarize characteristics that promote NP delivery to different cell types, and describe several therapeutic strategies for gene modification within the TME.
has issue date	2018-04-04(xsd:dateTime)
bibo:doi	10.3389/fphar.2018.00307
bibo:pmid	29670528
has license	cc-by
sha1sum (hex)	fa8f28950eb66ca369acb51e3cbb5b3ee178f82f
schema:url	https://doi.org/10.3389/fphar.2018.00307
resource representing a document's title	Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment
has PubMed Central identifier	PMC5893903
has PubMed identifier	29670528
schema:publication	Front Pharmacol
resource representing a document's body	covid:fa8f28950eb66ca369acb51e3cbb5b3ee178f82f#body_text
is schema:about of	named entity 'tumor' named entity 'nanoparticle' named entity 'size' named entity 'nanotechnology' named entity 'proven' named entity 'describe' named entity 'applications' named entity 'This' named entity 'cells' covid:arg/fa8f28950eb66ca369acb51e3cbb5b3ee178f82f named entity 'SIMILARITY' named entity 'T-LYMPHOCYTES' named entity 'METASTASIS' named entity 'CELL ACCUMULATION' named entity 'TARGET' named entity 'THERAPEUTIC' named entity 'SHAPE' named entity 'STIMULATION' named entity 'ABILITY' named entity 'CANCER GENE' named entity 'APPLICATIONS' named entity 'NPS' named entity 'EVIDENCE FOR' named entity 'CANCER' named entity 'CHALLENGES' named entity 'NANOPARTICLE' named entity 'LACKING' named entity 'RELEVANT' named entity 'IMMUNOTHERAPY' named entity 'EXPRESSION' named entity 'KILLING' named entity 'CONTROL' named entity 'CELLS' named entity 'MEDIATED' named entity 'NEW' named entity 'USED' named entity 'DIFFERENT' named entity 'ANTIGEN PRESENTING CELLS' named entity 'THESE' named entity 'IMMUNE' named entity 'PROMISE' named entity 'NANOTECHNOLOGY' named entity 'POTENTIAL' named entity 'BOOSTING' named entity 'EXAMPLE' named entity 'TME' named entity 'CIRCULATION' named entity 'ACCUMULATION' named entity 'STRATEGIES' named entity 'GENE MODIFICATION' named entity 'NUCLEIC ACID DELIVERY' named entity 'BEING' named entity 'EFFECTIVE' named entity 'DESCRIBE' named entity 'IMMUNE SYSTEM' named entity 'NON-' named entity 'TUMOR MICROENVIRONMENT' named entity 'TEMPORAL' named entity 'PHARMACEUTICAL' named entity 'TUMOR' named entity 'UPTAKE' named entity 'HAVE' named entity 'IMPORTANT' named entity 'VARIOUS' named entity 'INHIBITION' named entity 'PROGRESS' named entity 'ERA' named entity 'EFFECT' named entity 'CANCER CELLS' named entity 'CHALLENGE' named entity 'PHARMACOLOGY' named entity 'GIVEN' named entity 'INCREASING' named entity 'BUT' named entity 'MEDICINE' named entity 'JOURNAL '

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software